Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Pharvaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Characterization of Novel B2-Receptor Antagonists Published in Frontiers in Pharmacology","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Pharvaris"},{"company":"Pharvaris","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pharvaris Announces $80 Million Series C Financing to Advance Novel Oral Bradykinin-B2-Receptor Antagonists for the Treatment of HAE","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Pharvaris"},{"company":"Pharvaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharvaris Presents Clinical Data at ACAAI 2020 Demonstrating Safety and Therapeutic Potential of Oral PHA121 for the Treatment of HAE","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Pharvaris"},{"company":"EspeRare","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The EspeRare Foundation and Pierre Fabre Join Forces to Develop and Market a Pioneering Treatment for XLHED","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"EspeRare"},{"company":"Vaderis Therapeutics","sponsor":"Medicxi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaderis Therapeutics AG Emerges from Stealth and Announces Initiation of Clinical Proof-of-Concept Trial in HHT","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Vaderis Therapeutics"}]

Vaderis Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Vaderis Therapeutics AG Emerges from Stealth and Announces Initiation of Clinical Proof-of-Concept Trial in HHT

Details:

VAD044 is a once daily, orally administered, allosteric AKT inhibitor which has the potential to treat the underlying cause of Hereditary Haemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu Syndrome.

Lead Product(s): VAD044 L-Tartrate

Therapeutic Area: Genetic Disease Product Name: VAD044

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Medicxi

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 22, 2022

ASK
US

Upload
your Pipeline Activity

EspeRare

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

The EspeRare Foundation and Pierre Fabre Join Forces to Develop and Market a Pioneering Treatment for XLHED

Details:

The Pierre Fabre group will be granted exclusive worldwide rights for the development, manufacturing and commercialization of ER-004. EspeRare and the Pierre Fabre Group will pool their respective expertise together in order to co-develop ER-004.

Lead Product(s): ER-004

Therapeutic Area: Genetic Disease Product Name: EDI200

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Pierre Fabre

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration December 14, 2020

ASK
US

Upload
your Pipeline Activity

Pharvaris

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Pharvaris Announces $80 Million Series C Financing to Advance Novel Oral Bradykinin-B2-Receptor Antagonists for the Treatment of HAE

Details:

The proceeds from the Series C financing will fund the clinical advancement of Pharvaris’ pipeline of novel oral bradykinin-B2-receptor antagonists for the treatment of HAE, including both on-demand treatment and prophylactic prevention.

Lead Product(s): PHA-022121

Therapeutic Area: Genetic Disease Product Name: PHVS416

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Viking Global Investors

Deal Size: $80.0 million Upfront Cash: Undisclosed

Deal Type: Series C Financing November 18, 2020

ASK
US

Upload
your Pipeline Activity

Pharvaris

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Pharvaris Presents Clinical Data at ACAAI 2020 Demonstrating Safety and Therapeutic Potential of Oral PHA121 for the Treatment of HAE

Details:

The PK/PD profile suggests that rapid onset of action and prolonged efficacy with a single dose of PHA121 in the treatment of acute HAE attacks. Pharvaris is preparing to start an on-demand study of PHVS416, a soft capsule formulation of PHA121, for HAE attacks in 2021.

Lead Product(s): PHA121

Therapeutic Area: Genetic Disease Product Name: PHVS416

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 13, 2020

ASK
US

Upload
your Pipeline Activity

Pharvaris

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Preclinical Characterization of Novel B2-Receptor Antagonists Published in Frontiers in Pharmacology

Details:

The data set found in the publication demonstrates the preclinical profile of the new class of molecules relative to icatibant, an injectable B2-receptor antagonist used as the leading therapy for on-demand treatment of HAE.

Lead Product(s): PHA121

Therapeutic Area: Genetic Disease Product Name: PHA121

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 30, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY